Flexion picks up two more bullish ratings

|About: Flexion Therapeutics, ... (FLXN)|By:, SA News Editor

Wells Fargo initiates coverage of Flexion Theapeutics (FLXN) with an Outperform rating with a price target of $24 - $26 citing positive Phase 2 trial results of its lead product, FX006, a sustained-release injectable steroid for osteoarthritis pain.

Needham & Co. initiates coverage with a Buy rating and $26 price target.

The stock debuted on February 12.

Shares currently exchange hands at $19.